Enteric diseases are intestinal infections caused by a variety of bacteria, viruses and parasites when they enter the body through the mouth or intestinal systems such as salmonella, shigella, giardia lamblia, campylobacter, cryptosporidium and vibrio cholerae causing salmonellosis, shigellosis, giardiasis, campylobacteriosis, cryptosporidiosis and cholera, respectively.
The global enteric disease testing market is estimated to account for US$ 4,432.7 Mn in terms of value by the end of 2027.
Global Enteric Disease Testing Market: Drivers
High incidence of cholera is expected to propel growth of the global enteric disease testing market over the forecast period. For instance, according to United Nations High Commissioner for Refugees, in 2019, torrential rains and widespread flooding across Yemen led to more than 364,000 suspected cases of cholera and 639 deaths reported since the beginning of the year.
Moreover, outbreak of enteric disease is expected to boost demand for enteric disease testing. For instance, in August 2020, a salmonella outbreak was reported in 47 states in the U.S. The Centers for Disease Control and Prevention reported the number of reported cases of salmonella newport illnesses had grown to 869 cases, with 116 hospitalizations in 47 states in the third week of August.
North America held dominant position in the global enteric disease testing market in 2019, accounting for 38.5% share in terms of value, followed by Europe and Asia Pacific, respectively.
Figure 1: Global Enteric Disease Testing Market Share (%) Value, By Region, 2019
Global Enteric Disease Testing Market: Restraints
Lack of awareness regarding enteric disease, especially in emerging economies, is expected to hinder growth of the global enteric disease testing market.
Moreover, most of the people infected with enteric pathogens are asymptomatic or show mild symptoms. Mild nature of diseases let people ignore its diagnosis. Although, asymptomatic or mild nature of enteric diseases is good for human being but on the other hand it is considered as one of the major restraints affecting growth of the global enteric disease testing market.
|Base Year:||2019||Market Size in 2019:||US$ 3,643.4 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||2.5%||2027 Value Projection:||US$ 4,432.7 Mn|
Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech
|Restraints & Challenges:||
Global Enteric Disease Testing Market: Opportunities
Development of vaccines for bovine enteric diseases is expected to offer lucrative growth opportunities for players in the global enteric disease testing market. Diarrhea in calves may be highly fatal. If scours do not respond to commercial vaccines, autogenous vaccines may help.
Moreover, R&D in enteric diseases is also expected to boost demand for enteric disease testing. For instance, The International Centre for Diarrhoeal Disease Research, Bangladesh, and Emory University of the United States conducted studies in April 2017–January 2018 and April–October 2019 and found a high concentration of pathogens such as Escherichia coli, norovirus, Vibrio cholerae, shigella, Salmonella typhi and giardia in Bangladesh.
The global enteric disease testing market was valued at US$ 3,643.4 Mn in 2019 and is forecast to reach a value of US$ 4,432.7 Mn by 2027 at a CAGR of 2.5% between 2020 and 2027.
Figure 2: Global Enteric Disease Testing Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2019, Mobidiag Ltd., a molecular diagnostics company, received CE marking for its Novodiag Stool Parasites test. The new test is used for the detection of intestinal parasites directly from stool samples.
Outbreak of campylobacter infection is expected to propel growth of the global enteric disease testing market. For instance, in August 2020, Lindsay Farm, New Zealand, recalled raw drinking milk in New Zealand after one person needed hospital treatment for a Campylobacter infection.
Global Enteric Disease Testing Market: Competitive Landscape
Major players operating in the global enteric disease testing market include, Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech.
Global Enteric Disease Testing Market: Key Developments
Major players in the global enteric disease testing market are focused on approval and launch of new products to expand their product portfolio. For instance, in March 2019, ERADA Technology Alliance Ltd. (ERADA) launched saliva-based diagnostic tool, Saliva-based Malaria Asymptomatic and Asexual Rapid Test (SMAART), for detection of parasites causing malaria.
Enteric infection is a type of intestinal disease that causes symptoms ranging from mild gastroenteritis to systemic infections and severe diarrhea. According to WHO in 2017, Infectious gastroenteritis accounts for 1 billion cases of diarrhea globally and over 2 million deaths annually. In addition to this, according to Bill and Melinda Gates Foundation, 2017, enteric and diarrheal diseases leads to death of about 500,000 children, under the age of five each year, and children who survive repeated infections by gut pathogens in the early years of their life may suffer from lifelong health problems. This continuous rise in enteric infections among children is one of the major factors contributing to growth of the enteric disease testing market. Moreover, increasing launch of enteric disease testing products by key manufacturers is expected assist the growth of the market over the forecast period.
Key features of the study: